Gsk Share Discussion Threads

[montyhedge] 29/7/2020 09:26

Sanofi/GSK not being bias I think will be the winning vaccine. Sanofi great track record with influenza vaccines.

[alphorn] 29/7/2020 08:52

"expects a Phase 1/2 study to start in September"

Still at incredibly early stages. If successful, well into 2021 and seems behind the crowd.

[spud] 29/7/2020 08:51

Sanofi, GSK Agree With UK Government to Supply Up to 60 Million Doses of Covid-19 VaccineSource: Dow Jones News By Ian Walker Sanofi S.A. and GlaxoSmithKline PLC said Wednesday that they have reached an agreement with the U.K. government to supply up to 60 million doses of a Covid-19 vaccine, subject to final contract.The French and U.K. pharmaceutical companies said the vaccine candidate is based on Sanofi's technology that produces an influenza vaccine as well as GSK's pandemic adjuvant technology.Sanofi is leading clinical development and registration of the Covid-19 vaccine and plans a Phase 1, 2 study in September, followed by a Phase 3 study by the end of the year. If data proves positive, regulatory approval could be received in the first half of next year, it said.spud

[montyhedge] 29/7/2020 08:48

Of course they will set in stone, these quarterly dividends.

[tradermichael] 29/7/2020 08:39

How do you know that? They have not declared a dividend payment for 13 August - have to wait till after 12.00 noon today?

[montyhedge] 29/7/2020 08:31

Another 19p in the bag. Pharma's, software tech, gold, the only place to be in these markets.

[montyhedge] 29/7/2020 08:03

Yes I know.

[tradermichael] 29/7/2020 07:48

Monty: x div date will be 13 August .... ;0)

[our haven] 29/7/2020 07:25

Good news on the vaccine, promising potential.

[montyhedge] 28/7/2020 18:50

Markets expecting a 1% to 4% drop in revenue that's priced in at current shareprice.

[montyhedge] 28/7/2020 07:29

Quarterly figures should be half decent tomorrow. Another dividend in the bag.

[montyhedge] 27/7/2020 16:13

The only safe place to be Pharmas's and software Tech. Forget the rest of the market,
the only other good thing is gods currency, gold, silver etc.

[zeppo] 27/7/2020 15:04

abdulla

Boris says no pudding!

Satisfaction without the 'flim-flam' or flab?

Just good figures with optimism please.

[abdullla] 27/7/2020 14:45

Dividend safe or not we will taste the pudding on this Wednesday,good luck.

[montyhedge] 27/7/2020 14:24

Astra and GSK with AI helping with drugs, every rns seems to be a winner, AI helping with drug discovery and success, 2250p when re-rating comes. In the meantime collect a safe dividend.

[montyhedge] 27/7/2020 14:14

In these markets reassuring dividend on the doormat every 13 weeks.

[watfordhornet] 24/7/2020 16:48

Christ - you are lucky. Although down has held up better than most of mine this year. You not in any oil?

[tradermichael] 24/7/2020 16:24

Me too.

Next xd is 13 August (19p/share) ..... ;0)

[andyadvfn1] 24/7/2020 15:55

Added a few more today

[spoole5] 24/7/2020 15:48

Worst performing share i own. Sort it out emma

[tradermichael] 24/7/2020 15:26

Like this?:

GSK receives positive CHMP opinion recommending approval of belantamab mafodotin for the treatment of relapsed and refractory multiple myeloma

GlaxoSmithKline plc ( LSE/NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of belantamab mafodotin as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Dr Axel Hoos, Senior Vice President and Head of Oncology R&D, GSK said: "Today's positive opinion from the CHMP is an important step in helping patients suffering from relapsed or refractory multiple myeloma who currently have limited options and poor outcomes. If approved, belantamab mafodotin will provide patients and physicians across much of Europe with a first-in-class anti-BCMA treatment option that works differently from other available therapies for this incurable disease."

[essentialinvestor] 24/7/2020 15:14

Michael, think what markets are looking for is progress on the pharma pipeline.

[abdullla] 24/7/2020 14:13

Thanks TM.

[tradermichael] 24/7/2020 11:51

abdullla:

These respiratory products:
Theraflu,Otrivin,Flonase,Contac,Nicorette,Nicotinell,Nurses,Beechams,Piriton, Breathe Right


These pain and inflammatory products:
Voltaren, Voltarol, Panadol, Excedrin, Fenbid

These oral health products:
Aquafresh,Sensodyne,Corsodyl,Zovirax ('cold sore')

[ih_752952] 24/7/2020 10:52

DNL =3x Approvals expected during next 2 months including an Orphan Drug with FDA decision on September 29 = CHEAPEST UK Biotech a potential 500%++ GEM

Diurnal Group (DNL) = MCap £38 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping giant here .GL

Market Cap £38 million
Cash £15 million
Price 30p


Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29
EMA Decision for Chronocort expected in early Q1 2021